CL2019001047A1 - Metodo para evitar eventos cardiovasculares mediante la reduccion de la proproteinas convertasa subtilisina kexina 9 (pcsk9). - Google Patents

Metodo para evitar eventos cardiovasculares mediante la reduccion de la proproteinas convertasa subtilisina kexina 9 (pcsk9).

Info

Publication number
CL2019001047A1
CL2019001047A1 CL2019001047A CL2019001047A CL2019001047A1 CL 2019001047 A1 CL2019001047 A1 CL 2019001047A1 CL 2019001047 A CL2019001047 A CL 2019001047A CL 2019001047 A CL2019001047 A CL 2019001047A CL 2019001047 A1 CL2019001047 A1 CL 2019001047A1
Authority
CL
Chile
Prior art keywords
subject
cardiovascular disease
pcsk9
reducing
atherosclerotic cardiovascular
Prior art date
Application number
CL2019001047A
Other languages
English (en)
Inventor
Peter Wijngaard
David Kallend
Original Assignee
The Medicines Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Medicines Co filed Critical The Medicines Co
Publication of CL2019001047A1 publication Critical patent/CL2019001047A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen

Abstract

Método para reducir el colesterol de lipoproteínas de baja densidad o prevenir un evento cardíaco en un sujeto que tiene enfermedad cardiovascular aterosclerótica o que está en riesgo de padecer enfermedad cardiovascular aterosclerótica equivalente, que implica administrar al sujeto una cantidad profilácticamente efectiva de un agente de ARNi. Además, un método para prevenir el desarrollo de enfermedad cardiovascular aterosclerótica en un sujeto que implica administrar al sujeto una cantidad profilácticamente efectiva de un agente de ARNi. Además, un método para tratar a un sujeto que tiene enfermedad cardiovascular aterosclerótica o que está en riesgo de enfermedad cardiovascular aterosclerótica equivalente, que implica la administración al sujeto de una cantidad terapéuticamente efectiva de un agente de ARNi.
CL2019001047A 2016-10-18 2019-04-17 Metodo para evitar eventos cardiovasculares mediante la reduccion de la proproteinas convertasa subtilisina kexina 9 (pcsk9). CL2019001047A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662409816P 2016-10-18 2016-10-18
US201662422028P 2016-11-14 2016-11-14
US201762472525P 2017-03-16 2017-03-16
US201762550426P 2017-08-25 2017-08-25

Publications (1)

Publication Number Publication Date
CL2019001047A1 true CL2019001047A1 (es) 2020-05-08

Family

ID=60388127

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001047A CL2019001047A1 (es) 2016-10-18 2019-04-17 Metodo para evitar eventos cardiovasculares mediante la reduccion de la proproteinas convertasa subtilisina kexina 9 (pcsk9).

Country Status (12)

Country Link
US (2) US20180104360A1 (es)
EP (1) EP3529360B1 (es)
JP (2) JP7181881B2 (es)
KR (1) KR20190077411A (es)
CN (1) CN110088283A (es)
AU (2) AU2017346879B2 (es)
BR (1) BR112019007843A2 (es)
CA (1) CA3042423A1 (es)
CL (1) CL2019001047A1 (es)
IL (1) IL266066A (es)
MX (1) MX2019004573A (es)
WO (1) WO2018075658A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018002158A (es) 2015-08-25 2018-07-06 Alnylam Pharmaceuticals Inc Mí‰TODOS Y COMPOSICIONES PARA TRATAR UN TRASTORNO ASOCIADO A GEN DE PROPROTEINA CONVERTASA SUBTILISINA KEXINA (PCSK9).
US11492620B2 (en) 2017-12-01 2022-11-08 Suzhou Ribo Life Science Co., Ltd. Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof
WO2019105419A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
AU2018394875B2 (en) 2017-12-29 2023-08-03 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
EP3842534A4 (en) 2018-08-21 2022-07-06 Suzhou Ribo Life Science Co., Ltd. NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID AND METHOD OF USE THEREOF
EP3862024A4 (en) 2018-09-30 2022-08-17 Suzhou Ribo Life Science Co., Ltd. SHORT INTERFERENT RNA CONJUGATE, METHOD FOR PREPARATION AND USE THEREOF
JP2022533841A (ja) * 2019-05-22 2022-07-26 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、薬物組成物及び複合体ならびに調製方法と使用
CA3167849A1 (en) 2020-03-16 2021-09-23 Daniel Mitchell Antagonist of pcsk9
WO2024061157A1 (en) * 2022-09-19 2024-03-28 Kylonova (Xiamen) Biopharma Co., Ltd. Carbohydrate-oligonucleotide conjugates, pharmaceutical compositions, and therapeutic applications

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2874149T3 (es) * 2006-05-11 2021-11-04 Alnylam Pharmaceuticals Inc Composiciones y métodos para inhibir la expresión del gen PCSK9
LT2929031T (lt) * 2012-12-05 2018-02-12 Alnylam Pharmaceuticals, Inc. Pcsk9 irna kompozicijos ir jų naudojimo būdai

Also Published As

Publication number Publication date
MX2019004573A (es) 2019-10-07
AU2017346879A1 (en) 2019-05-23
EP3529360A1 (en) 2019-08-28
JP2022109948A (ja) 2022-07-28
JP7181881B2 (ja) 2022-12-01
BR112019007843A2 (pt) 2019-10-01
IL266066A (en) 2019-06-30
CN110088283A (zh) 2019-08-02
US20180104360A1 (en) 2018-04-19
WO2018075658A1 (en) 2018-04-26
KR20190077411A (ko) 2019-07-03
AU2017346879B2 (en) 2023-11-30
US20210093736A1 (en) 2021-04-01
CA3042423A1 (en) 2018-04-26
JP2019531357A (ja) 2019-10-31
AU2023263519A1 (en) 2023-12-07
EP3529360B1 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
CL2019001047A1 (es) Metodo para evitar eventos cardiovasculares mediante la reduccion de la proproteinas convertasa subtilisina kexina 9 (pcsk9).
CL2018001557A1 (es) Uso de un agente inhibidor de masp-2 que inhibe la activación del complemento dependiente de masp-2, para tratar un sujeto que padece de síndrome antifosfolipido catastrófico (safc). (solicitud divisional 201600908)
DOP2022000038A (es) Nanopartícula lipídicas mejoradas para el suministro de ácidos nucleicos
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
EA201892218A1 (ru) Способы ингибирования ангиогенеза у пациента
MX367325B (es) Composición farmacéutica que comprende un inhibidor de proproteína convertasa subtilisina kexina 9 (pcsk9) para usarse en un método para reducir el colesterol remanente y otras fracciones lipoproteicas.
MX2016011975A (es) Metodos para reducir el riesgo cardiovascular.
CL2015000699A1 (es) Métodos para tratamiento de cáncer.
CL2016002372A1 (es) Cenicriviroc para el tratamiento de la fibrosis.
ES2617920T3 (es) Métodos para el tratamiento de la coagulación intravascular diseminada mediante la inhibición de la activación del complemento dependiente de MASP-2
CL2013002874A1 (es) Metodo para tratar condiciones asociadas con la activacion del complemento dependiente de serino proteasa 2 asociada a la lactina de union a membrana (masp-2) mediante un agente inhibidor de masp-2, preferentemente u anticuerpo anti-(masp-2).
MX2021000898A (es) Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe).
BR112015022197A2 (pt) tratamento de cataplexia
BR112016014146A2 (pt) Métodos para formatar material fibroso e composições de tratamento para os mesmos
CL2016000378A1 (es) Composiciones y métodos terapéuticos para la regresión acelerada de placa
BR112019009726A2 (pt) terapias combinadas para aterosclerose, incluindo doença cardiovascular aterosclerótica
AR101740A1 (es) Terapia de combinación y composiciones
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
CL2015000418A1 (es) Formulacion acuosa topica que comprende un farmaco antiangiogenico que es un anticuerpo anti-vegf y un liposoma formado de un lipido a base de peg; su uso en el tratamiento de una enfermedad o condicion relacionada con vegf; y metodo para tratar cancer, psoriasis y edema macular diabetico, entre otras enfermedades.
BR112018075039A2 (pt) métodos de tratamento da síndrome de prader-willi
AR106530A1 (es) Métodos para tratar epilepsia
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
PE20151526A1 (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod
BR112016014182A2 (pt) Composições de ácidos graxos ômega 3 para tratar doenças que envolvem danos ao sistema nervoso
CL2018002097A1 (es) Tratamiento y diagnóstico de desórdenes inflamatorios